Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.91 CAD | +2.83% | +5.43% | +13.23% |
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.23% | 10.11M | - | - | |
+9.30% | 45.97B | B | ||
+52.73% | 43.93B | A | ||
+7.15% | 42.34B | B- | ||
-8.78% | 28.27B | C | ||
+18.68% | 27.18B | B- | ||
-21.92% | 19.44B | B | ||
+14.62% | 13.83B | C+ | ||
+31.85% | 12.4B | C+ | ||
+4.47% | 11.45B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Aeterna Zentaris Inc. - Toronto S.E.
- Ratings Aeterna Zentaris Inc.